Alere (ALR) has been under a strong bear grip, hence the stock is down -8.29% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.08% in the past 1 week. The stock has risen by 0.05% in the past week indicating that the buyers are active at lower levels, but the stock is down -7.94% in the past 4 weeks.
Alere Inc. has dropped 0.49% during the last 3-month period . Year-to-Date the stock performance stands at 3.53%. The stock has recorded a 20-day Moving Average of 3.57% and the 50-Day Moving Average is 0.39%.
Alere (NYSE:ALR): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $40.21 and $39.74 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $40.64. The buying momentum continued till the end and the stock did not give up its gains. It closed at $40.47, notching a gain of 0.65% for the day. The total traded volume was 677,932 . The stock had closed at $40.21 on the previous day.
Also, In a research note released to the investors, BTIG Research upgrades its rating on Alere (NYSE:ALR).The analysts at the brokerage house have a current rating of Buy on the shares. Earlier, the shares were rated a Neutral by the brokerage firm. In a recent information released to the investors, BTIG Research announces the price target of $48 per share. The rating by the firm was issued on August 8, 2016.
Alere Inc. is a provider of health information through diagnostic tests. The Company operates through professional diagnostics, patient self-testing, consumer diagnostics and, corporate and other segments. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The patient-self testing segment provides services designed to provide physicians with actionable data that allow them to make decisions in real time, deliver care, and put the individuals they treat on a pathway to better health. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its 50/50 joint venture with The Procter & Gamble Company (P&G).